Continuously Ingesting Fructooligosaccharide Can't Maintain Rats’ Gut Bifidobacterium at a High Level

Fructooligosaccharide (FOS) has been reported to increase Lactobacillus and Bifidobacterium populations in animal and human gut. Hence, it has been utilized to regulate the balance of gut microbiota. In this study, we compared the effects of high‐FOS (HFOS) diet on normal and obese rats’ gut Lactobacillus and Bifidobacterium, with high‐soybean‐fibers (HSF) diet as control. The results showed that the level of Bifidobacterium population substantially increased at week 4 in groups of rats fed the HFOS diet (P < 0.05), but significantly reduced to a small level at week 8 (P < 0.05); the abundance of Lactobacillus was increased in normal rats (P < 0.05), but decreased in obese rats (P < 0.05). The HSF diet did not promote the growth of Lactobacillus and Bifidobacterium in rats’ gut. The findings suggested that Bifidobacterium population could not be maintained at a high level when the rats continuously ingested the HFOS diet for 8 wk; additionally, Lactobacillus population could adapt to a relatively stable level with the consumption of HFOS diet.     

Erythropoietin Action in Stress Response,Tissue Maintenance and Metabolism

Erythropoietin (EPO) regulation of red blood cell production and its induction at reduced oxygen tension provides for the important erythropoietic response to ischemic stress. The cloning and production of recombinant human EPO has led to its clinical use in patients with anemia for two and half decades and has facilitated studies of EPO action. Reports of animal and cell models of ischemic stress in vitro and injury suggest potential EPO benefit beyond red blood cell production including vascular endothelial response to increase nitric oxide production, which facilitates oxygen delivery to brain, heart and other non-hematopoietic tissues. This review discusses these and other reports of EPO action beyond red blood cell production, including EPO response affecting metabolism and obesity in animal models. Observations of EPO activity in cell and animal model systems, including mice with tissue specific deletion of EPO receptor (EpoR), suggest the potential for EPO response in metabolism and disease.     

Obesity as a prospective predictor of depression in adolescent females.

Objective: Both obesity and depression are prominent during adolescence, and it is possible that obesity is a trigger for adolescent depression. The purpose of this paper is to evaluate whether overweight or obese status contributes to the development of depression in adolescent girls. Design: Participants were 496 adolescent girls who completed interview based measures of depression and had their height and weight measured at four yearly assessments. Repeated measures logistic regressions with generalized estimating equations were used to evaluate whether overweight or obese status were associated with major depression or an increase in depressive symptoms the following year. Main Outcome Measures: Major depression and depressive symptoms were evaluating using a modified version of the K-SADS interview. Overweight and obese status was determined by using standardized protocols to measure height and weight. Results: Results showed that obese status, not overweight status, was associated with future depressive symptoms, but not major depression. This study demonstrated that obesity is a risk factor for depressive symptoms, but not for clinical depression. Conclusions: As depressive symptoms are considered along the spectrum of depression with clinical depression at the high end, these results suggest that weight status could be considered a factor along the pathway of development of depression in some adolescent females. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Melatonin May Curtail the Metabolic Syndrome: Studies on Initial and Fully Established Fructose-Induced Metabolic Syndrome in Rats

To examine the effect of melatonin given to rats simultaneously with fructose on initial and fully developed metabolic syndrome, male Wistar rats had free access to chow and 5% or 10% fructose drinking solution for 8 weeks. As compared to controls, systolic blood pressure augmented significantly under both treatments whereas excessive body weight was seen in rats receiving the 10% fructose only. Rats drinking 5% fructose showed a greater tolerance to a glucose load while rats having access to a 10% fructose drinking solution exhibited the expected impaired glucose tolerance found in the metabolic syndrome. Circulating triglyceride and low density lipoproteins-cholesterol (LDL-c) concentration augmented significantly in rats showing a fully developed metabolic syndrome only, while high blood cholesterol levels were found at both stages examined. Melatonin (25 μg/mL drinking solution) counteracted the changes in body weight and systolic blood pressure found in rats administered with fructose. Melatonin decreased the abnormal hyperglycemia seen after a glucose load in 10% fructose-treated rats but it did not modify the greater tolerance to glucose observed in animals drinking 5% fructose. Melatonin also counteracted the changes in plasma LDL-c, triglyceride and cholesterol levels and decreased plasma uric acid levels. The results underline a possible therapeutical role of melatonin in the metabolic syndrome, both at initial and established phases.     

Altered Fatty Acid Metabolism-Related Gene Expression in Liver from Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease

Lipid accumulation in the human liver seems to be a crucial mechanism in the pathogenesis and the progression of non-alcoholic fatty liver disease (NAFLD). We aimed to evaluate gene expression of different fatty acid (FA) metabolism-related genes in morbidly obese (MO) women with NAFLD. Liver expression of key genes related to de novo FA synthesis (LXRα, SREBP1c, ACC1, FAS), FA uptake and transport (PPARγ, CD36, FABP4), FA oxidation (PPARα), and inflammation (IL6, TNFα, CRP, PPARδ) were assessed by RT-qPCR in 127 MO women with normal liver histology (NL, n = 13), simple steatosis (SS, n = 47) and non-alcoholic steatohepatitis (NASH, n = 67). Liver FAS mRNA expression was significantly higher in MO NAFLD women with both SS and NASH compared to those with NL (p = 0.003, p = 0.010, respectively). Hepatic IL6 and TNFα mRNA expression was higher in NASH than in SS subjects (p = 0.033, p = 0.050, respectively). Interestingly, LXRα, ACC1 and FAS expression had an inverse relation with the grade of steatosis. These results were confirmed by western blot analysis. In conclusion, our results indicate that lipogenesis seems to be downregulated in advanced stages of SS, suggesting that, in this type of extreme obesity, the deregulation of the lipogenic pathway might be associated with the severity of steatosis.     

Clinical Evaluation of Extracellular ADMA Concentrations in Human Blood and Adipose Tissue

Circulating asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, has been proposed as a biomarker for clinical outcome. Dimethylarginine dimethylaminohydrolase (DDAH) is the main enzyme responsible for ADMA metabolism and elimination. Adipose tissue ADMA concentrations and DDAH activity and their role in diabetes and obesity have not yet been investigated. In this study, we evaluated clinical microdialysis in combination with a sensitive analytical method (GC-MS/MS) to measure ADMA concentrations in extracellular fluid. Adipose tissue ADMA concentrations were assessed before and during an oral glucose tolerance test in lean healthy subjects and subjects with diabetes (n = 4 each), and in morbidly obese subjects before and after weight loss of 30 kg (n = 7). DDAH activity was determined in subcutaneous and visceral adipose tissue obtained during laparoscopic surgery (n = 5 paired samples). Mean interstitial ADMA concentrations did not differ between study populations (healthy 0.17 ± 0.03 μM; diabetic 0.21 ± 0.03 μM; morbidly obese 0.16 ± 0.01 and 0.17 ± 0.01 μM before and after weight loss, respectively). We did not observe any response of interstitial ADMA concentrations to the oral glucose challenge. Adipose tissue DDAH activity was negligible compared to liver tissue. Thus, adipose tissue ADMA plays a minor role in NO-dependent regulation of adipose tissue blood flow and metabolism.     

Caloric Restriction and Hypothalamic Leptin Gene Therapy Have Differential Effects on Energy Partitioning in Adult Female Rats

Dieting is a common but often ineffective long-term strategy for preventing weight gain. Similar to humans, adult rats exhibit progressive weight gain. The adipokine leptin regulates appetite and energy expenditure but hyperleptinemia is associated with leptin resistance. Here, we compared the effects of increasing leptin levels in the hypothalamus using gene therapy with conventional caloric restriction on weight gain, food consumption, serum leptin and adiponectin levels, white adipose tissue, marrow adipose tissue, and bone in nine-month-old female Sprague-Dawley rats. Rats (n = 16) were implanted with a cannula in the 3rd ventricle of the hypothalamus and injected with a recombinant adeno-associated virus, encoding the rat gene for leptin (rAAV-Lep), and maintained on standard rat chow for 18 weeks. A second group (n = 15) was calorically-restricted to match the weight of the rAAV-Lep group. Both approaches prevented weight gain, and no differences in bone were detected. However, calorically-restricted rats consumed 15% less food and had lower brown adipose tissue Ucp-1 mRNA expression than rAAV-Lep rats. Additionally, calorically-restricted rats had higher abdominal white adipose tissue mass, higher serum leptin and adiponectin levels, and higher marrow adiposity. Caloric restriction and hypothalamic leptin gene therapy, while equally effective in preventing weight gain, differ in their effects on energy intake, energy expenditure, adipokine levels, and body composition.     

The problem of obesity: fundamental concepts of energy metabolism gone awry.

The growing prevalence and complex issues related to obesity continue to draw the interest and concern of health researchers and practitioners. This review summarizes pertinent background information on the multiple factors involved in the causes of obesity. Factors such as percentage of body fat, upper- vs. lower-body obesity, family history, past dieting history, and underlying medical conditions should be assessed on an individual basis and applied in the development of successful weight-reducing strategies. The recommended approach to nonpharmacologic intervention for weight loss is to first educate individuals about fat storage and energy balance and then focus on the development of positive behavioral skills such as wise food selections, favorable eating patterns, and regular physical activity. Although preventive measures such as positive eating patterns and exercise habits are ideally acquired in childhood and adolescence, successful weight management can still be achieved in adulthood. The information presented in the following sections provides clinicians with essential material to assist individuals in developing realistic goals at the outset of a weight-control program.     

菌方普洱熟茶水提物和茶褐素的组成及其降脂作用

研究菌方普洱熟茶水提物和茶褐素的组成及对大鼠肥胖的调节作用。基于居里点热裂解气相色谱-质谱联用技术及高效液相色谱技术,分析菌方普洱熟茶水提物和茶褐素的组成成分。设置正常对照组、高脂模型组、菌方普洱熟茶水提物组和菌方茶褐素组,连续灌胃16周,分析SD大鼠生长指标、血清生化指标、氧化应激及炎症相关指标,并对肝脏组织HE和油红O染色切片进行观察。结果表明：菌方普洱熟茶水提物与茶褐素粗品中茶褐素、蛋白质和多糖占较大比重;没食子酸、表儿茶素和表没食子儿茶素没食子酸酯等儿茶素及衍生物类化合物含量存在明显差异（P<0.05）,菌方普洱熟茶水提物中生物碱类咖啡因和可可碱含量显著高于茶褐素粗品（P<0.05）;在不同居里点热裂解温度下,菌方普洱熟茶水提物与茶褐素的裂解产物分别有7种（380℃）和12种共同成分（600℃）,两者在不同温度下的裂解产物中,酚类种类最多,含量最高的化合物是咖啡因。与高脂模型组相比,菌方普洱熟茶水提物组和茶褐素组体质量、Lee’s指数显著减轻（P<0.05）,血清甘油三酯、血清空腹血糖、肝脏甘油三酯和胆固醇水平显著降低（P<0.05）,脂肪累积减少,血清...